Abstract
Autism is a neurodevelopmental disorder characterized by stereotyped interests and behaviors and abnormalities in verbal and nonverbal communication. Autism is reported as a multifactorial disorder resulting from interactions between genetic, environmental, and immunological factors. Excitotoxicity and oxidative stress are potential mechanisms, which are likely to serve as a converging point to these risk factors. Numerous studies suggest that excitotoxicity is a likely cause of neuronal dysfunction in autistic patients. Glutamate is the main excitatory neurotransmitter generated in the CNS, and overactivation of glutamate receptors triggers excitotoxicity. Hyperactivation of glutamatergic receptors, NMDA and AMPA, leads to activation of enzymes, which damage cellular structure, membrane permeability, and electrochemical gradients. The role of excitotoxicity in autistic subjects is summarized in this chapter.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Babu, G. N., Bawari, M., & Ali, M. M. (1994). Lipid peroxidation potential and antioxidant status of circumventricular organs of rat brain following neonatal monosodium glutamate. Neurotoxicology, 15, 773–777.
Bachevalier, J. (1994). Medical temporal lobe structures and autism. A review of clinical and experimental findings. Neuropsychologia, 32(6), 627–648.
Baxter, P., Griffiths, P., Kelly, T., & Gardner-Medwin, D. (1996). Pyridoxine dependent seizuer; demographic clinical, MRI and psychometric feature, and affect of dose on intelligent quotient. Dev. Med. Chil Neurol. 38(11), 998–1006.
Baron-Cohen, S., Scott, F. J., Allison, C., Williams, J., Bolton, P., Matthews, F. E., & Brayne, C. (2009). Prevalence of autism-spectrum conditions: UK school-based population study. The British Journal of Psychiatry, 194, 500–509.
Blaylock, R. L. (2003). The central role of excitotoxicity in autism spectrum disorders. The Journal of the American Nutraceutical Association, 6, 7–19.
Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22, 574–579.
Cohly, H. H., & Panja, A. (2005). Immunological findings in autism. International Review of Neurobiology, 71, 317–341.
Ekonomou, A., & Angelatou, F. (1999). Upregulation of NMDA receptors in hippocampus and cortex in the pentylenetetrazol-induced “kindling” model of epilepsy. Neurochemical Research, 24, 1515–1522.
Eliasson, M. J., Huang, Z., & Ferrante, R. J. (1999). Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. The Journal of Neuroscience, 19, 5910–5918.
Espey, M. G., Kustova, Y., Sei, Y., & Basile, A. S. (1998). Extracellular glutamate levels are chronically elevated in the brains of LPBM5-infected mice: A mechanism of retrovirus-induced encephalopathy. Journal of Neurochemistry, 71, 2079–2087.
Farooqui, A. A., & Horrocks, L. A. (1994). Excitotoxicity and neurological disorders: Involvement of membrane phospholipids. International Review of Neurobiology, 36, 267–323.
Fontana, A., Constam, D., Frei, K., et al. (1996). Cytokines and defense against CNS infection. In R. M. Ransohoff & E. N. Beneviste (Eds.), Cytokines and the CNS. Boca Raton: CRC Press. ISBN ISBN-10: 0849324521.
Fosslier, E. (2001). Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Annals of Clinical and Laboratory Science, 31, 25–67.
Gillberg, C., & Coleman, M. (2000). The biology of autistic syndromes (3rd ed.). London: Mac Keith (distributed by Cambridge University Press), New York: Mac Keith Press.
Gospe, S. M., & Hecht, S. T. (1998). Longitudinal MRI findings in pyridoxine dependent seizures. Neurology, 51, 74–78.
Henneberry, R. C. (1989). The role of neuronal energy in neurotoxicity of excitatory amino acids. Neurobiology of Aging, 10, 611–613.
Hu, H., Shao, L. R., Chavoshy, S., Gu, N., Trieb, M., Behrens, R., Laake, P., Pongs, O., Knaus, H. G., Ottersen, O. P. et al. (2001). Glutamatergic hippocampul terminals and their role in spike repolarization and regulation of transmitter nllase. J. Neurosci., 15:21(24), 9585–9597.
Johnston, M. V. (1995). Neurotransmitters and vulnerability of the developing brain. Brain & Development, 17, 301–306.
Lan, J. Y., Skeberdis, V. A., Jover, T., Grooms, S. Y., Lin, Y., Araneda, R. C., et al. (2001). Protein kinase C modulates NMDA receptor trafficking and gating. Nature Neuroscience, 4, 382–390.
Mathern, G. W., Pretorius, J. K., Mendoza, D., et al. (1999). Hippocampal N-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients. Annals of Neurology, 46, 343–358.
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988). Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Research, 451, 205–212.
O’Banion, M. K. (1999). Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Critical Reviews in Neurobiology, 13, 45–82.
Olney, J. W. (1969). Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science, 165, 719–721.
Olney, J. W., Collias, R. C., & Sloviter, R. S. (1986). Excitotoxic mechanism of epileptic brain damage. Advances in Neurology, 44, 857–877.
Page, L. A., Daly, E., Schmitz, N., Simmons, A., Toal, F., Deeley, Q., Ambery, F., McAlonan, G. M., Murphy, K. C., & Murphy, D. G. M. (2006). In Vivo1H-magnetic resonance spectroscopy study of Amygdala-Hippocampal and Parietal regions in autism. The American Journal of Psychiatry, 12, 2189–2192.
Rogawski, M. A. (1995). Excitatory amino acids and seizures. In T. W. Stone (Ed.), CNS neurotransmitters and neuromodulators: Glutamate (pp. 219–237). Boca Raton: CRC Press.
Saitoh, O., Karns, C. M., & Courchesne, E. (2001). Development of the hippocampal formation from 2 to 42 years: MRI evidence of smaller area dentata in autism. Brain, 124, 1317–1324.
Shinohe, A., Hashimoto, K., Nakamura, K., et al. (2006). Increased serum levels of glutamate in adult patients with autism. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 1472–1477.
Zilbovicius, M., Boddaert, N., Belin, P., et al. (2000). Temporal lobe dysfunction in childhood autism: A PET study. The American Journal of Psychiatry, 157, 1988–1993.
Acknowledgments
The work has been partly supported by Sultan Qaboos University Internal grant (Grant # IG/AGR/FOOD/11/02) and the Research Council, Oman (Grant # RC/AGR/FOOD/11/01). This work has been also supported by the Alzheimer’s Association (grant # IIRG- 08–89545) and by the Rebecca Cooper Foundation (Australia). Dr. Nady Braidy is the recipient of an Alzheimer’s Australia Viertel Foundation Postdoctoral Research Fellowship at the University of New South Wales.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Essa, M.M., Braidy, N., Subash, S., Vijayan, R.K., Guillemin, G.J. (2014). Excitotoxicity in the Pathogenesis of Autism. In: Kostrzewa, R. (eds) Handbook of Neurotoxicity. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5836-4_148
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5836-4_148
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5835-7
Online ISBN: 978-1-4614-5836-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences